BioNTech Moves to Full Control as CureVac Tender Clears Major Hurdles

CureVac is undergoing a decisive transformation, shifting from an independent mRNA pioneer to a fully integrated unit within BioNTech. With the pivotal steps in motion, the takeover is effectively moving toward completion. For shareholders, the key question is what the present terms mean for their stake.

BioNTech Wins a Clear Majority

The takeover was effectively settled through the exchange tender. By the close of the first acceptance window, 184,071,410 CureVac shares had been tendered, representing about 81.74% of the issued and outstanding capital. This level meets the minimum acceptance threshold, clearing the path for the subsequent reorganization.